A Multiple-dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0148-0287 C (Insulin 287) for Subcutaneous Administration in Japanese Subjects With Type 1 Diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Aug 2019
Price : $35 *
At a glance
- Drugs Insulin 287 (Primary) ; Insulin glargine
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Novo Nordisk
- 20 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 21 Dec 2018 Status changed from not yet recruiting to recruiting.
- 11 Dec 2018 New trial record